Dr. Rami Yacoub Haddad, MD

Dr. Haddad practices at Affiliated Oncologists in Hazel Crest, Illinois.

Dr. Haddad's NPI, 1710072624, was assigned on October 4, 2006. Dr. Haddad graduated from University of Jordan Faculty of Medicine in 1996. Dr. Haddad holds Illinois license 036-115280.

Dr. Haddad's primary practice is Affiliated Oncologists, at 17850 Kedzie Ave, Hazel Crest, IL 60429 in Cook County. The practice phone is (310) 335-4000.

Dr. Haddad's primary practice is Affiliated Oncologists in Hazel Crest, Illinois. Dr. Haddad is also affiliated with Advocate Christ Medical Center. The medical group on file is Affiliated Oncologists. Dmand AI also links Dr. Haddad to 4 more hospitals and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Haddad practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Haddad's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Haddad is board certified in geriatric medicine by the American Board of Internal Medicine. Dmand AI has Dr. Haddad's licenses on file in 3 states: Illinois, Missouri and Texas.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, immune deficiency disease, lung cancer, lymphoma and multiple myeloma among the conditions Dr. Haddad treats.

CMS data shows 83,184 Medicare services from Dr. Haddad across 39 procedure codes in 2024, for 557 Medicare patients. Medicare paid $1,701,156 for them.

CMS counts 557 Medicare patients who saw Dr. Haddad in 2024. The largest group is 75 to 84, with 242 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 16% are also on Medicaid. Their average risk score is 2.24, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Haddad's median patient age at 71, with 64% women.

In 2024, Dr. Haddad wrote 1,702 Medicare Part D claims for 298 patients. 58% of them were for generic drugs. CMS names the drug for 1,412 of them, across 32 drugs with 11 or more claims each, at $4,744,967 in total drug cost. In 2023, CMS named 1,105 claims across 28 drugs.

Dr. Haddad accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 8 papers to Dr. Haddad, published from 2018 to 2022. The most frequent topics are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms and Protein Kinase Inhibitors. Dr. Haddad has published most often in Dis Mon. Dr. Haddad's most frequent co-authors are Paul J. Hesketh, MD, Dharamvir Jain, MD and David H. Johnson, MD.

Dmand AI links Dr. Haddad to 3 clinical trials. 2 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Squamous Cell Carcinoma of Head and Neck. Open Payments lists research payments to Dr. Haddad that name 1 trial.

CMS Open Payments shows 1,862 general payments to Dr. Haddad from 95 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 43% of the total. AstraZeneca Pharmaceuticals LP paid the most, $9,952. It also lists 1 research payment totaling $2,614 in 2021, naming 1 clinical trial.

Dmand AI lists 1 award for Dr. Haddad, most recently Research Award in 2006.

Dr. Haddad graduated from University of Jordan Faculty of Medicine in 1996. Dr. Haddad is a member of ACP, ASCO, ASH and European Society of Medical Oncology.

Dr. Haddad is in network with 19 carriers, including Aetna, Elevance and HCSC. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.